Rationale for a T cell receptor peptide therapy in myasthenia gravis.
Jambou
F
F
CNRS UMR 8078, IPSC, Université Paris XI, Hôpital Marie Lannelongue, Le Plessis-Robinson, France.
Menestrier
M
M
Klingel-Schmitt
I
I
Caillat-Zucman
S
S
Aïssaoui
A
A
Berrih-Aknin
S
S
Cohen-Kaminsky
S
S
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D004797:Enzyme-Linked Immunosorbent Assay; D015803:HLA-DR3 Antigen / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000378:metabolism; D007223:Infant; D009157:Myasthenia Gravis / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D010455:Peptides / Q000627:therapeutic use; D011948:Receptors, Antigen, T-Cell / Q000145:classification / Q000276:immunology / Q000627:therapeutic use*; D013952:Thymus Hyperplasia / Q000097:blood / Q000150:complications / Q000628:therapy
D015803:HLA-DR3 Antigen; D007074:Immunoglobulin G; D010455:Peptides; D011948:Receptors, Antigen, T-Cell